Trial reportTranslational psychiatry2021
A double-blind placebo-controlled trial of minocycline on translocator protein distribution volume in treatment-resistant major depressive disorder.
Trial report in Translational psychiatry, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 2 syntheses or guidelines pooled it, 17 citations in OpenAlex.
- Effect of Anti-Inflammatory Treatment on Depressive Symptom Severity and Anhedonia in Depressed Individuals With Elevated Inflammation: Systematic Review and Meta-Analysis of Randomized Controlled Trials.The American journal of psychiatry · 2026Pooled it
- Meta-analysis of molecular imaging of translocator protein in major depression.Frontiers in molecular neuroscience · 2022Pooled it
- Trial
- Tomentosin selectively targets microglial pyroptosis to overcome fluoxetine-resistant depression: a network-based therapeutic discovery.Translational psychiatry · 2026Article
- Imaging brain inflammation and blood brain barrier permeability in neurological and psychiatric diseases: a review.Journal of neuroinflammation · 2025Review
- Inflammatory and Immune Biomarkers in Mood Disorders: From Mechanistic Pathways to Clinical Translation.Cells · 2025Review
- Advancing precision psychiatry and targeted treatments: Insights from immunopsychiatry.Brain, behavior, and immunity · 2025Review
- Efficacy of inflammation-based stratification for add-on celecoxib or minocycline in major depressive disorder: Protocol of the INSTA-MD double-blind placebo-controlled randomised clinical trial.Brain, behavior, & immunity - health · 2024Article
- Efficacy and acceptability of anti-inflammatory agents in major depressive disorder: a systematic review and meta-analysis.Frontiers in psychiatry · 2024Review
- Cool the Inflamed Brain: A Novel Anti-inflammatory Strategy for the Treatment of Major Depressive Disorder.Current neuropharmacology · 2024Review
- Inflammation, stress and depression: An exploration of ketamine's therapeutic profile.Drug discovery today · 2023Review
- Normalization of Neuroinflammation: A New Strategy for Treatment of Persistent Pain and Memory/Emotional Deficits in Chronic Pain.Journal of inflammation research · 2022Review
- Dopamine and Neuroinflammation in Schizophrenia - Interpreting the Findings from Translocator Protein (18kDa) PET Imaging.Neuropsychiatric disease and treatment · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Gliosis is implicated in the pathophysiology of many neuropsychiatric diseases, including treatment-resistant major depressive disorder (TRD). Translocator protein total distribution volume (TSPO V
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.